Jump to ContentJump to Main Navigation
Show Summary Details
Weitere Optionen …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Hrsg. v. Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
Alle Formate und Preise
Weitere Optionen …
Band 41, Heft 12

Hefte

The Application of Clinical Proteomics to Cancer and other Diseases

William Clarke / Zhen Zhang / Daniel W. Chan
Online erschienen: 01.06.2005 | DOI: https://doi.org/10.1515/CCLM.2003.239

Abstract

The term “clinical proteomics” refers to the application of available proteomics technologies to current areas of clinical investigation. The ability to simultaneously and comprehensively examine changes in large numbers of proteins in the context of disease or other changes in physiological conditions holds great promise as a tool to unlock the solutions to difficult clinical research questions. Proteomics is a rapidly growing field that combines high throughput analytical methodologies such as two-dimensional gel electrophoresis and SELDI mass spectrometry methods with complex bioinformatics to study systems biology–the system of interest is defined by the investigator. Even with all its potential, however, studies must be carefully designed in order to differentiate true clinical differences in protein expression from differences originating from variation in sample collection, variation in experimental condition, and normal biological variability. Proteomic analyses are already widely in use for clinical studies ranging from cancer to other diseases such as cardiovascular disease, organ transplant, and pharmacodynamic studies.

Artikelinformationen

Online erschienen: 01.06.2005

Erschienen im Druck: 04.12.2003


Quellenangabe: Clinical Chemistry and Laboratory Medicine, Band 41, Heft 12, Seiten 1562–1570, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2003.239.

Zitat exportieren

Zitierende Artikel

Hier finden Sie eine Übersicht über alle Crossref-gelisteten Publikationen, in denen dieser Artikel zitiert wird. Um automatisch über neue Zitierungen dieses Artikels informiert zu werden, aktivieren Sie einfach oben auf dieser Seite den „E-Mail-Alert: Neu zitiert“.

[1]
Cristina Núñez
Clinica Chimica Acta, 2019, Jahrgang 490, Seite 113
[2]
Ziad J. Sahab, Suzan M. Semaan, and Qing-Xiang Amy Sang
Biomarker Insights, 2007, Jahrgang 2, Seite 117727190700200
[3]
Rikke Leth-Larsen, Rikke R. Lund, and Henrik J. Ditzel
Molecular & Cellular Proteomics, 2010, Jahrgang 9, Nummer 7, Seite 1369
[4]
Amalia Vioque-Fernández, Eduardo Alves de Almeida, and Juan López-Barea
Biomarkers, 2009, Jahrgang 14, Nummer 5, Seite 299
[5]
Ran Wang, Shuai Huang, Jing Li, and Junseok Chae
Applied Physics Letters, 2014, Jahrgang 105, Nummer 14, Seite 143703
[6]
Yaşam Barlak, Orhan Değer, Meltem Çolak, Senem Karataylı, Abdurrahman Bozdayı, and Fulya Yücesan
Proteome Science, 2011, Jahrgang 9, Nummer 1, Seite 74
[7]
Christoph Röcken, Matthias P.A Ebert, and Albert Roessner
Pathology - Research and Practice, 2004, Jahrgang 200, Nummer 2, Seite 69
[8]
Svetlana Ignjatovic
Jugoslovenska medicinska biohemija, 2006, Jahrgang 25, Nummer 2, Seite 119
[10]
Maimuna Mendy and Robert Walton
Cancer Letters, 2009, Jahrgang 286, Nummer 1, Seite 44
[11]
Mario Plebani
Clinica Chimica Acta, 2005, Jahrgang 357, Nummer 2, Seite 113
[12]
Therese Rosenling, Amos Attali, Theo M. Luider, and Rainer Bischoff
Clinica Chimica Acta, 2011, Jahrgang 412, Nummer 11-12, Seite 812
[13]
Ashima Sinha, Chetna Singh, Devendra Parmar, and Mahendra Pratap Singh
Life Sciences, 2007, Jahrgang 80, Nummer 15, Seite 1345
[14]
Emily I. Chen and John R. Yates
Molecular Oncology, 2007, Jahrgang 1, Nummer 2, Seite 144
[15]
Ann L. Miracle and Gerald T. Ankley
Reproductive Toxicology, 2005, Jahrgang 19, Nummer 3, Seite 321
[16]
Anu Kalia and R. P. Gupta
Critical Reviews in Biotechnology, 2005, Jahrgang 25, Nummer 4, Seite 173
[17]
Marie-Christine W. Gast, Carla H. van Gils, Lodewijk F.A. Wessels, Nathan Harris, Johannes M.G. Bonfrer, Emiel J.Th. Rutgers, Jan H.M. Schellens, and Jos H. Beijnen
Clinical Chemistry and Laboratory Medicine, 2009, Jahrgang 47, Nummer 6
[18]
Svetlana Ignjatovic
Jugoslovenska medicinska biohemija, 2006, Jahrgang 25, Nummer 2, Seite 119
[19]
Marie-Christine W. Gast, Jan H. M. Schellens, and Jos H. Beijnen
Breast Cancer Research and Treatment, 2009, Jahrgang 116, Nummer 1, Seite 17
[20]
Sergio Ciordia, Vivian de los Ríos, and Juan-Pablo Albar
Clinical and Translational Oncology, 2006, Jahrgang 8, Nummer 8, Seite 566
[21]
Tiphaine Monsinjon and Thomas Knigge
PROTEOMICS, 2007, Jahrgang 7, Nummer 16, Seite 2997
[22]
Jia-Xiang Wang, Jie-kai Yu, Li Wang, Qiu-Liang Liu, Jiao Zhang, and Shu Zheng
PROTEOMICS, 2006, Jahrgang 6, Nummer 19, Seite 5344
[23]
Gary L. Nelsestuen, Yan Zhang, Michael B. Martinez, Nigel S. Key, Bernd Jilma, Michael Verneris, Alan Sinaiko, and Raj S. Kasthuri
PROTEOMICS, 2005, Jahrgang 5, Nummer 15, Seite 4012
[24]
Jens Koopmann, Paul J. Thuluvath, Marianna L. Zahurak, Troels Z. Kristiansen, Akhilesh Pandey, Richard Schulick, Pedram Argani, Manuel Hidalgo, Stefano Iacobelli, Michael Goggins, and Anirban Maitra
Cancer, 2004, Jahrgang 101, Nummer 7, Seite 1609

Kommentare (0)